MedTrace Logo

Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness

NCT07356986 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-01-21

No results posted yet for this study

Summary

The purpose of this prospective observational study is to gather exploratory and practical use data of the Dexcom Stelo Glucose Biosensing System (Stelo), an over-the-counter (OTC) real-time Continuous Glucose Monitoring (CGM) system among patients with Gestational Diabetes Mellitus (GDM) in their most recent pregnancy.

Conditions

  • Gestational Diabetes
  • Postpartum

Interventions

DEVICE

Dexcom Stelo real-time Continuous Glucose Monitor

The Stelo Glucose Biosensor is an over-the-counter integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. Participants will use Stelo for the 6 weeks following delivery and for 15 days at 3 months, 6 months, 9 months, and 1 year postpartum.

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • University of Pennsylvania

    collaborator OTHER

  • Sansum Diabetes Research Institute

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Amy M Valent, DO, MCR · Oregon Health and Science University

  • Celeste Durnwald, MD · University of Pennsylvania

  • Kristin Castorino, DO · Sansum Diabetes Research Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07356986 on ClinicalTrials.gov